Product Images Atorvastatin Calcium

The text is a medication label indicating the dosage and manufacturer information for atorvastatin calcium tablets. It instructs pharmacists to dispense patient information along with the medication in a child-resistant container and store the tablets at room temperature. There is also a link provided for printing patient information.*

NDC 51407-079-90 is a medication containing atorvastatin calcium, USP equivalent to 20 mg atorvastatin in each film-coated tablet. The prescribing information should be consulted for dosing information. The tablets should be stored in a child-resistant container at 20° - 25°C (68° - 77°F). Keep out of the reach of children. Patient information should be provided with each dispensing. Manufactured by ScieGen Pharmaceuticals and marketed by GSMS, Incorporated. For additional information, visit the website listed.*

NDC 51407-080-90 is a medication containing atorvastatin calcium with a dosage of 40 mg. Patients should refer to the accompanying Calcium Prescribing Information for proper usage instructions. The medication is manufactured by ScieGen Pharmaceuticals, Inc. and distributed by GSMS, Inc. Patients should be given the Patient Information by the pharmacist and the medication should be kept in a child-resistant container at a temperature of 20° - 25°C.*

This is a description of medication containing atorvastatin calcium with a dosage of 80mg per tablet. The prescribing information is available and the patient information should be printed from the given website. It is manufactured by ScieGen Pharmaceuticals, Inc. and marketed by GSMS, Incorporated. It should be kept in a child-resistant container and out of reach of children. The recommended storage temperature is between 20-25°C.*

This appears to be a figure showing the effect of Atorvastatin Calcium 10 mg/day on the cumulative incidence of non-fatal myocardial infarction or coronary heart disease death over the course of 35 years in the ASCOT-LLA study. It shows a hazard ratio of 0.64 at a significance level of p=0.0005. No further information is available.*

This is a graph labeled "Figure 2" that shows the effect of Atorvastatin Calcium 10 mg/day on the Time to Occurrence of Major Cardiovascular Event in the CARDS study. The study measured myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke. The x-axis is labeled "Time to First Primary Endpoint Through Four (4) Years of Follow-up (Years)" and the y-axis is labeled "Cumulative Hazard (%)." The graph shows a decrease in the hazard of a major cardiovascular event over time with a HR of 0.63, which was statistically significant with p<0.001.*

This is a graph showing the effect of two different doses of Atorvastatin Calcium (80mg/day and 10mg/day) on the time it takes for major cardiovascular events to occur in subjects. The x-axis represents the time to the first major cardiovascular endpoint (in years), and the y-axis shows the percentage of subjects experiencing an event. The results indicate that the higher dose had a statistically significant effect in reducing the occurrence of major cardiovascular events compared to the lower dose.*